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Vaccinehave prompted calls for more preclinical vaccine testing in non-human primates.
However, similar to HIV infection of humans, developing a vaccine that protects macaques from infection
following pathogenic SIVMAC251 challenge has proven difﬁcult, and current vaccine candidates at best, only
reduce viral loads after infection. Here we demonstrate that prior infection with a chimeric simian–human
immunodeﬁciency virus (SHIV) containing an HIV envelope gene confers protection against intravenous
infection with the heterologous, highly pathogenic SIVMAC251 in rhesus macaques. Although deﬁnitive
immune correlates of protection were not identiﬁed, preservation and/or restoration of intestinal CD4+
memory T cells were associated with protection from challenge and control of viremia. These results suggest
that protection against pathogenic lentiviral infection or disease progression is indeed possible, and may
correlate with preservation of mucosal CD4+ T cells.
© 2009 Elsevier Inc. All rights reserved.IntroductionAlthough it has been over 25 years since the beginning of the AIDS
epidemic, an effective vaccine remains elusive. To date, all HIV-1 vaccine
candidates tested in humans have failed to prevent infection or
meaningfully impact viral replication (Koff et al., 2006). Furthermore,
most vaccine approaches evaluated in non-human primate models,
including protein subunits, inactivated particles, DNA, and recombinant
live vectors, alone or in various combinations, have shown at best only
limited, partial efﬁcacy, particularly in studies involving stringent
challenges with pathogenic SIV strains such as SIVMAC239, SIVMAC251 or
SIVSME660 (Casimiro et al., 2005; Eganet al., 2000;Hortonet al., 2002;Koff
et al., 2006; Larke et al., 2005). The recent disappointing failure of the
STEP clinical trial of the Merck Ad5 vectored candidate vaccine, despite
inductionof readilymeasurable virus speciﬁc cellular immune responses,
emphasizes that we still do not understand the basis of protective
immunity against HIV infection (Cohen, 2007; Watkins, 2008).
In contrast, use of live attenuated viruses as vaccines has
demonstrated more robust protection from rigorous homologous
and heterologous viral challenges in macaques, thus providing criticalll rights reserved.proof-of-concept for the feasibility of an HIV vaccine to prevent or
limit HIV infection (Abel et al., 2003; Connor et al., 1998; Daniel et al.,
1992; Koff et al., 2006; Kumar et al., 2002; Marthas et al., 1992; Mori
et al., 2001; Wyand et al., 1996). However, most of these studies
utilized relatively insensitive methods for viral detection, or protec-
tion was deﬁned as a reduction of ~1 log plasma viral load compared
to controls. Moreover, relatively few studies have investigated the
potential mechanisms of this protectionwith contemporary assays for
virus-speciﬁc cellular immune assays or antiviral antibody. Abel et al.
(2003) have demonstrated that “immunization” with the attenuated
virus SHIV89.6 can confer protection in a signiﬁcant fraction of animals
against subsequent intravaginal (IVAG) challenge with the highly
pathogenic SIVMAC239, demonstrating that protection can be achieved
against mucosal transmission of a highly pathogenic partially
heterologous virus that is sequence divergent in env and regulatory
genes. However, since the challenge was IVAG, it is not clear whether
this protection was attributable to mucosal or systemic immunity. A
model that demonstrated protection against intravenous (IV) chal-
lenge would provide even more evidence that protection against
highly pathogenic SIV challenge is achievable, and would allow
assessment of the role of systemic immune responses in such control.
Our recent study showed that rhesus macaques were highly
susceptible to vaginal transmission of SHIV162P3, yet ~90% had low
Fig. 1. Experimental design of the SHIV162P3 inoculation and SIVMAC251 challenge. SHIV infected macaques were subsequently intravenously challenged with different dosages of
pathogenic SIVMAC251 on the days post inoculation indicated in three separate experiments. For controls, four naïve Chinese origin macaques were concurrently inoculated with
SIVMAC251 (highlighted in red).
Fig. 2. Plasma viral RNA levels in macaques after primary SHIV162P3 infection, prior to
pathogenic SIVMAC251 challenge. All animals had high primary viremia 14–21 days after
vaginal inoculation, which declined to low or undetectable levels by 70 days of
infection. Viral loads were undetectable in 6 out of the 14 animals by 70 days post
inoculation.
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et al., 2007). We hypothesized that these animals may thus be
“immunized” against subsequent challenge with SIVMAC251, which
could provide a model for assessing correlates of immunity to this
highly pathogenic challenge. Alternatively, we hypothesized that prior
infection could immunocompromise animals, and result in an
exacerbated course of infection in response to SIVMAC251 challenge,
thus providing a model for studying HIV “superinfection”, deﬁned as
when a currently HIV-infected person becomes infected with a second
strain of HIV from a subsequent exposure.
While superinfection of HIV-1 infected patients with a second strain
of HIV-1 has implications for vaccine development (Gottlieb et al.,
2007), superinfection can be difﬁcult to prove, as it is often difﬁcult to
distinguishwhether viral variants are the result of subsequent infection
or simply represent mutations of the initial infecting virus (Gottlieb
et al., 2007). Furthermore, the consequences of superinfection remain
unclear (Gottlieb et al., 2007). Non-human primate models provide an
opportunity to address these questions in an experimentally tractable
fashion. Here we demonstrate that macaques primarily infected with
the minimally pathogenic virus SHIV162P3 conferred partial to complete
protection against subsequent IV challenge with the highly pathogenic
SIVMAC251. Furthermore, we demonstrate that mucosal CD4+memory T
cells were maintained following pathogenic challenge, suggesting that
mucosal immune responses play a role in this protection. Finally, these
results indicate that immunity to infectionwith SIV/HIVmay indeed be
possible, and additional studies with these and similar models of
protection may provide insights into the immune correlates of
protection from HIV infection.
Results
“Immunization” with SHIV162P3
Rhesus macaques of Indian (InRh) or Chinese (ChRh) origin were
atraumatically inoculated intravaginally with 300 TCID50 SHIV162P3
and conﬁrmed to be infected, as evidenced by high peak plasma
viremia between 14 and 21 days post inoculation ranging from 0.45 to
6.3×106 viral RNA (vRNA) copies/ml plasma, proving that none of the
animals were genetically “resistant” to SHIV/SIV infection (Figs. 1
and 2). Viral loads were undetectable in 6 out of 14 SHIV162P3
inoculated animals by 70 days post inoculation (Fig. 2). All macaques
were followed for 89 to 345 days post inoculation, until plasma viral
load (VL) declined to levels from undetectable to 7600 vRNA copies/
ml of plasma. This initial infection is subsequently referred to as the
“immunization” phase.In a series of three sequential experiments, all “immunized”
macaques were then intravenously challenged with SIVMAC251. The
three experiments were designed to determine whether the dose,
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rechallenge. In the ﬁrst experiment (Group A), seven previously
“immunized” macaques (four ChRh and three InRh) were IV
challenged with a high dose (100 TCID50) of SIVMAC251. On the day
of challenge, the InRh macaques (AK46, R191 and T552) had
higher residual plasma VLs from the prior SHIV162P3 immunization
(0.03–0.76×104 vRNA copies/ml of plasma) compared to the four
ChRh macaques, two of which had undetectable (AJ61 and DT93) or
very low levels (340–650 vRNA copies/ml plasma) on the day of
challenge (Fig. 3A). As a concurrent control, a naïve (non-immunized)
ChRhmacaque (V780) was IV inoculated with 100 TCID50 of SIVMAC251.
Following challenge, one ChRh macaque (DT93) showed no
measurable viremia (b30 vRNA copies/ml) through N640 days of
follow-up. The other 3 ChRh macaques showed excellent control of
viral replication, with plasma viremia 2–3 logs lower than the naïve
control throughout primary infection. All seven macaques immunized
by prior infection with SHIV162P3 showed greater levels of resistance
or control of the high dose IV SIVMAC251 challenge, at least through
154 days of challenge (Fig. 3A). In addition, ﬁve of the sevenmacaques
did not demonstrate a “peak” of viremia in the ﬁrst weeks following
challenge. Only two macaques (InRh macaque T552 and ChRh
macaque AJ61) showed any increased viremia after SIVMAC251
challenge. Plasma viremia declined or remained low in one macaqueFig. 3. Plasma viral RNA levels in macaques following SIVMAC251 challenge. Plasma viremia i
Plasma viral loads from individual experiments (A) and mean±SE of the mean viral loads fo
in non-immunized, control macaques (red lines) compared to immunized macaques durin
SIVMAC251 challenge. Plasma viral load from the 3 InRh in Group A is presented as a dashed lin
100TCID50 SIVMAC251 are shown as dashed purple line.(DT55) throughout 154 days after challenge and increased thereafter
(Fig. 3A). These results suggest that substantial control of viremia
following a high dose IV challenge with a pathogenic, heterologous
virus can be achieved through prior immunization with an atte-
nuated/weakly pathogenic SHIV.
The second experiment (Group B) was designed to determine if
greater control could be achieved following a lower IV challenge. Four
ChRh macaques previously “immunized” by SHIV162P3 infection, and
one SIV-naïve ChRh control were IV inoculated with 10 TCID50 of the
same SIVMAC251 challenge stock used in Group A. On the day of
challenge, all four “immunized”macaques had undetectable (FA10) or
low levels of plasma viremia (40–340 vRNA copies/ml). Following IV
SIVMAC251 challenge, three out of four immunized macaques had no
signiﬁcant increase in plasma viremia over pre-challenge levels (i.e.,
no peak viremia), and their vRNA was intermittently undetectable in
plasma (b30 vRNA copies/ml) on multiple occasions (Figs. 3A and B).
Plasma VLs in CF58 remained less than 1000 copies/ml after challenge
through day 42, but then gradually climbed to approximately 10,000
copies/ml by day 285 and this animal developed AIDS 2.5 years after
SIV challenge (Fig. 3A). The three remaining SHIV immunized and
SIVMAC251 challenged macaques in this group have remained healthy
through 3 years of follow-up, and have had undetectable plasma
viremia. In contrast, the naïve ChRh control macaque had high peaks reported as log10 vRNA copies per ml of plasma (detection limit 30 vRNA copies/ml).
r each of the different groups (B) are shown. Note there was signiﬁcantly higher viremia
g early (day 14), steady state (day 42) and late (day 282) stages of infection following
e. (B) Mean plasma viral loads from 4 historical naive ChRh intravenously infected with
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control in Group A, and both controls were subsequently euthanized
with signs and lesions of AIDS. Combined, the results of studies in
Group A (high IV dose) and B (low IV dose) demonstrated that
resistance to IV superinfection (1 macaque in group A) and/or
remarkable control of plasma viremia (3 macaques in Group B) could
be conferred by prior infection with a virus having a divergent
envelope. Moreover, even in animals that were persistently infected,
plasma viremia remained 1–3 logs lower during the early phase of
infection than in control macaques inoculated with the same lot and
route of virus.
To rule out potential artifacts of immune control resulting from
using ChRh vs. InRh hosts, the third experiment (Group C) utilized an
inoculum passaged in ChRh. Plasma VLs have been shown to be lower
in ChRh than InRh macaques inoculated with SIV grown in InRh
peripheral blood mononuclear cells (PBMC) (Ling et al., 2002), and
thus the differences we observed could be due to adaptive “ﬁtness” of
the particular stocks for InRh macaque cells. Thus, we challenged ﬁve
ChRh macaques intravenously with 1 ml plasma containing ~2.0×106Fig. 4. (A) Cell-associated viral RNA levels in jejunum LPL in macaques following SIVMAC251
intestinal tissues at the day of SIVMAC251 challenge in SHIV immunized macaques. By 21, 56
challenged macaques, whereas SHIV162P3 immunized macaques had low to undetectable ti
survival curves for the immunized and non-immunized macaques in all three groups af
macaques compared to controls. Survival comparisons were performed using a log-rank tesvRNA copies/ml of SIVMAC251 which was obtained from a ChRh
macaque on a serial passage study. This experiment was also
important to compare the results of virus obtained from plasma
compared to in vitro expanded viral stocks in generating infection and
potential differences in protection from this challenge.
Of the 5 ChRh macaque animals inoculated with ChRh macaque-
derived plasma virus, three were previously “immunized” with
SHIV162P3 and two were naïve controls. Of the three “immunized”
macaques, two had undetectable plasma viremia (b30 vRNA
copies/ml), while one (L375) had 1600 copies/ml remaining at the
time of challenge. Following challenge, both animals with undetect-
able viremia on the day of challenge continued to control viremia to
less than 1000 copies/ml after challenge. The third (L375) also
demonstrated VLs 1–2 logs lower than the naïve controls until day
190 post challenge (p.c.) (Fig. 3A) but then plasma VL increased to
levels similar to naïve challenged macaques. In contrast, both naïve
controls demonstrated uncontrolled viral replication and 1 log
higher vRNA plasma copies compared to that of the controls in
Groups A and B (Fig. 3A).challenge (detection limit 30 vRNA copies). There was low to undetectable viremia in
and 104 days post SIVMAC251 challenge increased viral replication was noticed in naïve
ssue viral load. Mean tissue VLs are shown with a line in each plot. (B) Kaplan–Meier
ter SIVMAC251 challenge demonstrating signiﬁcantly increased survival of immunized
t.
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were detected between controls and immunized challenged maca-
ques (p=0.003–0.015 Fig. 3B). When the InRh were excluded from
the analysis, these differences were even more signiﬁcant. Prior
immunization with SHIV162P3 resulted in a 1.8 to 3.7-log reduction in
plasma VLs in all immunized macaques compared to naive controls
through 156 days p.c. regardless of whether animals were challenged
with high or low IV doses, or SIVMAC infected plasma (Fig. 3B).
We also examined cell-associated viral loads in intestinal lympho-
cytes on a subset of the animals where sufﬁcient cells were available
(Fig. 4A). Copies of SIVgag RNA were low (FA14, 50 copies of SIVgag
RNA) to undetectable in both SHIV immunized and naïve challenged
macaques (Fig. 4A) on the day of SIVMAC251 challenge. By 21 days post
challenge all 3 immunized macaques had low (FA14, 90 copies of
SIVgag RNA) to undetectable levels of virus whereas, naïve challenged
macaques (FG46 and FA06) had much higher levels in intestinal
tissues (Fig. 4A). Similar differences in intestinal VLs were detected in
both SHIV immunized and naïve challenged macaques after 56 and
104 days of SIVMAC251 challenge (Fig. 4A).
There was also a highly signiﬁcant difference in survival between
immunized and naïve macaques (p=0.009) (Fig. 4B). Of the 14
“immunized” macaques challenged with SIV, 5 remain alive and
healthy (3 years since challenge); ﬁve were euthanized for unrelated
reasons 2 years after infection (with no detectable plasma viremia or
clinical signs related to SIV infection). Only 4 immunized animals
were euthanized with AIDS deﬁning illnesses (DT55, T552, CF58 andFig. 5. Dynamics of CD4+ Tcell percentages in peripheral blood (A) and axillary lymph node (
non-immunized (naïve) challenged macaques had a rapid decrease in CD4+ T cells by day 14
preserved in immunized macaques. InRh macaques are delineated by dashed lines.L375). In contrast, all 4 of the SIV naïve control ChRh macaques were
euthanized due to AIDS-deﬁning illnesses (opportunistic infection,
lymphoma, and/or SIV encephalitis) within 14 months of challenge.
Maintenance of systemic and intestinal CD4+ T cells in
immunized macaques
Although animals in groups A–Cwere challengedwith SIVMAC251 at
very different time points after SHIV162P3 immunization, all were
challenged at time points when plasma VLs had declined to low or
undetectable levels. To assess whether the limitation of viral
replication observed in SHIV162P3 immunized animals following SIV
challenge reﬂected a paucity of viral target cells induced by the initial
SHIV162P3 infection, percentages of total CD4+ T cells were compared
in peripheral blood (PB), intestine (jejunum) and axillary lymph node
(LN) in naïve and SHIV immunized macaques immediately prior to,
and subsequent to SIV challenge. Prior to challenge, percentages of
total CD4+ cells in blood were stable in all animals (mean CD4+ T cell
% in group A, B and C was 51.7% (range 28.7–63.6), 56.4% (range 49.5–
67.2) and 54.7% (range 49.3–62.2) respectively), reﬂecting the low
level of plasma viremia at the time of challenge. Total CD4+ T cell
populations in LN alsowere relatively normal in immunizedmacaques
at the time of challenge. Following SIVMAC251 challenge, percentages of
CD4+ T cell counts dropped signiﬁcantly (pb0.01) in the PB of all
naïve controls, yet remained stable in all immunized animals through
at least 119 days p.c. (Fig. 5A). However, six macaques (AK46, CF58,B) of immunized and non-immunized macaques following SIVMAC251 challenge. Note all
after challenge in both peripheral blood and LN (red lines) whereas CD4+ T cells were
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250–402 days after challenge, which inversely correlated with
increasing VLs at these timepoints. Similarly, there were decreased
percentages of CD4+ T cells in the LN of naïve macaques, yet CD4+ T
cells remained fairly stable in immunized macaques (Fig. 5B).
Surprisingly, percentages of CD4+ Tcells in the intestine at the time
of challenge were highly variable in immunized animals, yet they did
not appear to correlate with levels of plasma viremia. Several SHIVFig. 6. (A) A representative dot plots showing CD4+ T cells as a percentage of total T cells (ga
that restoration and/or preservation of intestinal CD4+ Tcells was observed in a SHIV immun
was rapid and sustained loss of intestinal CD4+ T cells within 14 days of challenge. The per
intestinal CD4+ T cells of immunized and non-immunized macaques following challenge wit
in all non-immunized (highlighted in red) compared to immunized macaques by day 14-poimmunized macaques had lower levels of CD4+ T cells in intestinal
lamina propria lymphocytes (LPL) compared to naïve controls at the
timeof challenge. Selective depletion of intestinal CD4+T lymphocytes
following SHIV162P3 infection has been previously reported (Hsu et al.,
2003). Intestinal CD4+ T cell percentages were similar in groups A
(mean 25%, ranged from 10.0–42.1%) and B (mean 26.7%, ranged from
12.3–39.7%) whereas naive macaques V780 and V302 had around 33%
intestinal CD4+ T cells at the time of SIVMAC251 challenge (Figs. 6Ated through CD3+ lymphocytes) in macaques (Group B) after SIVMAC251 challenge. Note
ized macaque (FA08) compared to the non-immunized macaque (V302), inwhich there
centage of CD3+CD4+ T cells is indicated in the top box of each panel. (B) Changes in
h SIVMAC251. Note that in all groups, there was a rapid decrease in intestinal CD4+ T cells
st challenge. Intestinal CD4+ T cells of InRh are shown as dashed lines.
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pared to animals in both A and B but not signiﬁcantly different
(p=0.62) (Fig. 6B). The two naïve controls in group C had higher
(∼43%) intestinal CD4+ T cells at the day of challenge (Fig. 6B).
Following SIVMAC251 challenge, essentially all SHIV-immunized maca-
quesmaintained near baseline levels of intestinal CD4+ Tcells through
at least 42 days of infection,whereas all naïvemacaques demonstrated
marked and persistent reductions in intestinal CD4+ T cells (Figs. 6A
and B). In fact, percentages of intestinal CD4+ Tcells increased by day 7
and 14 in several SHIV-immunized macaques (Fig. 6B). The main
exceptions were in immunized macaques DT93 and R191, which
showed moderate drops in intestinal CD4+ T cells by 14 days post
challenge, yet these returned to baseline levels in the following weeks
(Fig 6B). Similarly, macaques CF58 and FA05 had a transient drop in
percentages of intestinal CD4+ T cells 7 days after challenge, yet these
animals also recovered to levels higher than at the time of SIV
challenge, indicating eventual control of replication in mucosal sites
(Fig. 6B). Memory (CD45RA−) CD4+CCR5+ T cells in the intestine, the
major early targets for SIV/HIV infection and replication (Brenchley
et al., 2004; Mattapallil et al., 2005; Veazey et al., 2000a,b;Wang et al.,
2007) were also relatively maintained in SHIV-infected macaques at
the time of challenge (Figs. 7A and B) suggesting that the limitation of
viral replication observed following pathogenic challenge was notFig. 7. (A) Percentages ofmemory (CD45RA−) CD4+CCR5+ Tcells in the intestine of a represen
and 14 days after SIVMAC251 challenge. Note the marked and rapid decrease in intestinal target
whereas these cells are maintained in the immunized macaque. Percentages of CCR5+ and CD
(gated through CD3+ lymphocytes) are shown for groups A–C. Note a rapid decrease in CD4+CC
14 days of SIVMAC251 challenge, whereas target cells are preserved in immunized macaques. Inattributable to a paucity of viral target cells. Overall, intestinal CD4+ T
cell percentages from all naive control macaques (groups A–C)
demonstrated marked and signiﬁcant losses by 14 days after chal-
lenge with SIVMAC251 (p=0.007), whereas immunized macaques did
not change signiﬁcantly. Similarly, a highly signiﬁcant difference
(p=0.009) in the availability of CD4+CCR5+ target cells was detected
between SHIV immunized and naïve challenged macaques by 14 days
after SIV challenge indicating that immunized animals had a bona ﬁde
“resistance” to infection, associated with preservation/restoration of
mucosal viral target cells (Figs. 6 and 7).
Investigations into potential “immune” control of SIV challenge
Several studies have suggested that neutralizing antibodies (Nabs)
and/or T cell responses can play a role in controlling viral infection
(Ferrantelli et al., 2004a,b; Koup et al., 1994; Mascola et al., 2005;
Schmitz et al., 1999). Nabs against the immunizing SHIV162P3, the
SIVMAC251 challenge, as well as to laboratory-adapted SIVMAC251 were
measured for all macaques from groups A, B and C. However, neither
SHIV-immunized or naïve challenged macaques produced signiﬁcant
levels of Nab to SHIV or SIVMAC251 in any of the groups examined. Only
one macaque (T552) had a transient low level of Nabs to SIVMAC251
4weeks after infection, but Nab titers ranged from b20 to 67 in all othertative SHIV immunized (FA08) and non-immunized, naive (V302)macaque before (day 0)
cells (CD3+CD4+CCR5+CD45RA−) typical of naïve macaques challenged with SIVMAC251,
45RA+ T cells are shown in each quadrant. (B) Percentages of intestinal CD4+CCR5+ cells
R5+ Tcells occurs in all non-immunized challengedmacaques (highlighted in red) within
testinal CD4+CCR5+ T cells of InRh are shown as dashed lines.
Table 1
Antigen speciﬁc IFN-γ responses on the day of SIVMAC251 challenge from groups A and
C macaquesa.
aMacaques in red were unvaccinated (naïve) followed by SIVMAC251 challenge. Other
macaques were infected with SHIV162P3 followed by SIVMAC251 challenge. Values
represent responses to speciﬁc peptide pools; =HIV-Tat, ●=SIV-Nef, ■=SIV-Gag,
▲=SHIV-gp120, and❖=SHIV-gp41. Numbers indicate spot forming cells per 1million
PBMCs after medium-only control values were subtracted.
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were detected to the SIVMAC251 infection in naive challenged macaques.
On the day of SIVMAC251 challenge, antigen speciﬁc IFN-γ responses
to tat, gag, nef, and env were examined in PB, LN and intestine of all
SHIV162P3 immunized macaques in groups A and C. Overall, 90% ofTable 2
Antigen speciﬁc IFN-γ responses in SIVMAC251 challenged macaques in peripheral blooda.
aPeptide-speciﬁc responses are depicted for PBMCs in 1 million cells, medium control subt
and C macaques as indicated, only positive responses are shown. Macaques with red fontsSHIV immunized animals demonstrated positive responses to SIV-gag
followed by SHIV-env (70%) and HIV-tat (20%) antigens (Table 1).
Despite these responses, neither the magnitude nor the presence of
SHIV-env and/or SIV-gag IFN-γ responses present at the time of
challenge correlated with the level of viral control following SIVMAC251
challenge.
Following challenge, IFN-γ responses in PB were monitored by
ELISPOT for N118 days in groups A and C, and in selected animals,
through 84 days of infection in lymph nodes (Tables 2 and 3). In
general, gag-speciﬁc responses were higher in immunized macaques
followed by SIV tat, nef, gp120 and gp41 responses (Tables 2 and 3).
SIV-env speciﬁc IFN-γ responses were detected in PBMC as early as
21 days after challenge, but only in one macaque (AK46). Similarly, 7
out of 10 immunized macaques had detectable antigen speciﬁc IFN-γ
responses by day 14 after challenge in LN. However, there was no
correlation between control of plasma vRNA and IFN-γ responses in
any of the immunized or control macaques (r2 ranged from 0.006 to
0.86 and p=0.06 to 0.89). We have also performed one way analysis
of variance of the number of IFN-γ secreting cells in both vaccinated
and unvaccinated challenged macaques in all the time point of this
study but no signiﬁcance difference in the number of IFN-γ positive
cells at any time point (pN0.05) has been established.
Discussion
Correlates of immunity or resistance to HIV infection remain
unknown. This has hampered efforts to produce an effective vaccine.
The aim of a vaccine would be to prevent infection, ameliorate disease
course, and/or reduce virus transmission. The risk of transmission is
greatest when viremia is high, especially during acute, and uncon-
trolled chronic infection. Infected individualswith plasmaVLs of b1700
copies/ml fail to transmit the virus to theirHIV-negative partners (Gray
et al., 2003, 2001). An effective HIV vaccine should at least be able toracted. Although all peptide pools (SIV tat, nef, gag and env) were tested for groups A
depicted unvaccinated challenged macaques. ND=not determined.
Table 3
Antigen speciﬁc IFN-γ responses in SIVMAC251 challenged macaques in lymphocytes
isolated from lymph nodea.
aPeptide-speciﬁc responses are reported for lymphocytes isolated from lymph nodes in
1 million cells, medium control subtracted. Although all peptide pools (SIV tat, nef, gag
and env) were tested for groups A and C macaques as indicated, only positive responses
are shown. Macaques with red fonts are depicted as unvaccinated challenged. ND=not
determined.
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(Wilson et al., 2006). Although some vaccine candidates have shown
modest reductions in VLs in macaques after SIV challenge, these were
usually performed under ideal conditions using homologous viral
challenges or against less than optimal SHIV's (Casimiro et al., 2005;
Koff et al., 2006; Letvin et al., 2006; Mattapallil et al., 2006; Watkins
et al., 2008; Wilson et al., 2006). However, a more recent study has
shown partially effective control of viremia by a live attenuated SIV
followed by IV challenge with a heterologous SIV (Reynolds et al.,
2008). Moreover, the studies here also demonstrate that signiﬁcant
levels of protection from an IV heterologous challenge with a highly
pathogenic strain of SIV in macaques is indeed possible, at least in a
proportion of macaques. Although the immunogen used in this study
was a replication-competent SHIV known to cause AIDS in a proportion
of macaques, the results demonstrate that the SHIV immunization
prolonged the survival and/or delayed disease progression after
challenge with SIVMAC251. Furthermore, the fact that control of viremia
persisted formonths after levels of the immunizing virus had subsided,
combined with the observation that mucosal viral target cells are at
least partially restored prior to challenge, and more importantly,
maintained after pathogenic challenge, suggests this control is asso-
ciatedwith immune responses rather than a phenomenon of target cell
depletion. Low to undetectable viral replication in intestinal tissues also
suggested thatmaintenance/restoration of CD4+CCR5+memory Tcell
targets was associated with control of the SIV challenge.
Unfortunately, we could not determine the correlates of immunity
in these animals. Neither levels of plasma Nabs, nor virus speciﬁc
systemic or mucosal IFN-γ responses correlated with protection.
However, the fact that the envelope of the immunizing virus markedly
differs from the challenge virus indicated that protection was not
associated with immune responses directed against the envelope. This
may be an additional source of optimism, as it is unlikely that a vaccine
can be engineered to generate responses to all of the diverse HIV
envelope sequences encountered in endemic areas. Thus, vaccines
might not have to be matched for all possible envelope sequences in
order to confer protection.
One caveat that must be considered is whether this “protec-
tion” is indeed due to inducible immune responses or instead, viral
competition for viral binding or integration sites. In this and prior
studies, “protection” appears to be associated with persistence oflow levels of virus or antigen in tissues. Conceivably, integrated
virus could somehow prevent “superinfection” of target cells by
either competition for integration sites, or by mediating cellular
machinery to prevent subsequent infection or replication within
infected cells. In fact, the lower levels of memory CD4+CCR5+
target cells in intestinal tissues of SHIV162P3 immunized animals at
the time of SIV challenge suggested that there may be persistent
viral replication in the gut, even though our analysis of cell-
associated virus did not demonstrate signiﬁcant levels of viral RNA
in these animals (Fig. 4A).
However, there is some evidence that this protection is mediated
by adaptive immune responses. The fact that “immunized” animals
maintained memory CD4+CCR5+ T cells in intestinal tissues follow-
ing SIV challenge, in contrast to naïve controls who showed a signi-
ﬁcantly greater degree of intestinal CD4 depletion, suggests that the
protection observed is not due to a limitation of target cells necessary
to establish productive superinfection. Furthermore, all controls
became infected, maintained high VLs, and progressed to AIDS,
proving that this is not an artifact of macaques of Chinese origin,
which have a higher incidence of long term nonprogression than
macaques of Indian origin (Ling et al., 2007). In addition, this
protection is not attributed to immune responses directed against
foreign host major histocompatibility complex (MHC) proteins
incorporated into the viruses, as the effects were the same whether
the viral inoculum was grown in InRh macaque cells or passaged in
ChRh. Finally, four immunized macaques did demonstrate transient
slight (FA05, CF58) to moderate (DT93, R191) drops in mucosal CD4+
T cells immediately following SIV challenge, suggesting virus was
reaching intestinal CD4+ T cells, and that there was an initial struggle
in mucosal sites for control of local viral replication (Fig. 6). Unlike
infected naïve controls, all four of these animals eventually restored
mucosal CD4+ T cells to levels higher than at the time of challenge
(Fig. 6). In summary, these studies provide evidence that protection
against a highly pathogenic strain of SIV may be achieved, and
suggest that this protection may be associated with adaptive mucosal
immune responses (Casimiro et al., 2005; Kawada et al., 2007;
Wilson et al., 2006).
These studies also argue against the hypothesis that super-
infection results in a more severe disease progression (Altfeld et al.,
2002; Gottlieb et al., 2007; Jost et al., 2002; Smith et al., 2004; van
der Kuyl et al., 2005). The challenge virus used in these studies
(SIVMAC251) is among the most pathogenic of viruses in macaques,
and if infection with one virus impairs immune responses against a
second virus, we should have observed an enhancement of disease
progression following SIV challenge. However, VLs were clearly
diminished in the superinfected animals compared to controls,
indicating that the primary infection confers some type of protection
against superinfection and disease progression. In summary, this
model may prove useful for understanding superinfection as well as
correlates of immunity to HIV infection in humans. Although we are
not promoting the use of attenuated viruses as vaccine candidates,
we propose that such models may eventually help deﬁne correlates
of immunity to infection, which could eventually guide HIV vaccine
development.
Materials and methods
Macaques
Fifteen adult female Chinese rhesus (ChRh) and three Indian
rhesus (InRh) (AK46, R191 and T552) macaques (Macaca mulatta)
were housed at the Tulane National Primate Research Center in
accordance with the regulations of the American Association for
Accreditation of Laboratory Animal Care International. All animals
were healthy and free from SIV, STLV and Type D retrovirus at the time
the study was initiated.
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A series of three experiments was performed to determine
whether macaques previously infected with SHIV162P3 were suscep-
tible to subsequent “superinfection” with pathogenic SIV (Fig. 1).
SHIV162P3 is a chimeric virus constructed from a SIVMAC239 template,
yet it contains functional HIV-1 tat, rev and env genes (Harouse
et al., 2001, 1999). Although IV inoculation of macaques with high
doses of this virus occasionally results in persistent viremia and
AIDS (Harouse et al., 2001, 1999), in our experience, vaginal
inoculation with SHIV162P3 usually results in transient viremia and
apparent “clearance” of virus within 70–90 days of infection (Pahar
et al., 2007). To determine whether macaques previously infected
with SHIV162P3 were susceptible to IV “superinfection” with
pathogenic SIV, a total of fourteen infected macaques (11 of ChRh
and 3 InRh) and 4 naïve controls (all ChRh) were IV challenged with
SIVMAC251. For the IVAG primary infections (“immunization” phase)
macaques used as placebo controls in microbicide experiments
were ﬁrst treated with Depo Provera (depomedroxyprogesterone
acetate) and 30–33 days later, sedated and intravaginally inoculated
with 300 TCID50 SHIV162P3 obtained from the NIH AIDS Research
and Reagent Program (Pahar et al., 2007; Veazey et al., 2003). All 14
animals became infected as evidenced by high peak viremia 14–
21 days after inoculation (Fig. 2). Macaques were then followed for
89–345 days post inoculation, until plasma viral loads declined to
low (b7600 vRNA copies/ml) or undetectable levels. In three
separate experiments, infected animals and controls were IV
challenged with a high (group A) and low (group B) dose of
SIVMAC251 and plasma from a SIV-infected macaque of ChRh origin
(group C).
In the ﬁrst experiment (group A), seven SHIV162P3 infected (4 ChRh
and 3 InRh) and one-naïve ChRh macaques were IV challenged with
100 TCID50 SIVMAC251. In subsequent experiments all macaques
(immunized and controls) were of Chinese origin. In the second
experiment (group B), 4 SHIV162P3 infected and 1-naïve macaques
were IV challenged with a lower dose (10 TCID50) of SIVMAC251. The
SIVMAC251 challenge stock used in both A and B was grown in Indian
origin macaque PBMC, and thus to rule out the possibility that the
results observed were an artifact of using virus grown in MHC-
mismatched hosts, animals in the third experiment were challenged
with plasma obtained in primary infection from a ChRh macaque
infected with SIVMAC251. In this experiment (group C), three SHIV
infected and two naive macaques were IV challenged with 1 ml of
plasma containing 2×106 vRNA copies/ml.
Quantitation of plasma and cell associated viral RNA
Plasma VL during pre-challenge time points was quantiﬁed by a
bDNA signal ampliﬁcation assay, version 4.0, speciﬁc for SIV, from
Bayer Inc., which has a threshold detection limit of 125 copies/ml of
plasma (Pahar et al., 2007). After SIVMAC251 challenge, plasma VL and
cell-associated SIVgag RNA copies were determined by a sensitive
real-time RT-PCR method as previously described (Cline et al., 2005)
(limit of detection as used in the present study, 30 RNA copies/ml).
Isolation of lymphocytes from blood, intestine and lymph nodes
Lymphocytes from the PB, jejunum and axillary LNwere isolated as
described earlier (Veazey et al., 2000a,b; Wang et al., 2008). In brief,
intestinal biopsies were obtained by endoscopy and digested with
serial incubations with EDTA and collagenase with rapid agitation. To
enrich for intestinal LPL, cells were centrifuged over discontinuous
Percoll (Sigma) density gradients, washed, and resuspended in
complete RPMI media containing 5% FCS (RPMI-5). Intestinal
lymphocytes were N90% viable as assessed by Trypan blue dye
exclusion.Lymphocytes were isolated from axillary LN by mincing with
paired scalpel blades and pressing them through nylon cell mesh. Cells
were washed twice and resuspended in RPMI-5.
T cell immunophenotyping
T cell immunophenotyping was performed using CD3-FITC/PerCP
(SP34-2), CD4-APC (L200), CD8-PE/PerCP (RPA-T8), CCR5 PE (3A9)
and CD45RA FITC (5A9), all from BD Biosciences. For surface staining,
100 μl of EDTA whole blood was incubated with titrated mAb for
30 min on ice. Red blood cells were lysed with 1× FACS lysing buffer
(BD Biosciences) using a whole blood lysis technique as previously
described (Pahar et al., 2006).
Intestinal LPL and LN lymphocyteswere adjusted to 107 cells/ml and
100 μl aliquots were incubatedwith appropriately diluted antibodies for
30 min on ice, washed, and ﬁxed in 2% paraformaldehyde. Cells were
protected from light at 4 °Cand acquisitionwas completedwithin24hof
staining. Data were acquired on a FACS Calibur ﬂow cytometer (BD
Biosciences, SanJose, CA) using Cell Quest software. At least 20,000
eventswere collected bygatingon lymphocytes, anddatawere analyzed
using FlowJo software (TreeStar Inc.) version 8.5.3.
ELISPOT assay
The number of antigen-speciﬁc IFN-γ spot forming cells (SFC) was
measured with a commercial ELISPOT assay speciﬁc for rhesus IFN-γ
(U-Cytech, Utrecht, The Netherlands), using fresh heparinized PBMC
or lymphocytes isolated from LNs or intestinal lamina propria as
previously described (Pahar et al., 2003, 2007; Van Rompay et al.,
2004). Peptides (15-mers with 11 amino acids overlap) derived from
the HIV-tat (cat. 5138), SIV-tat (cat. 6207), SIV-nef (cat. 8762), SIV-gag
(cat. 6204), SIV-env (cat. 6883) and SHIV162P3 env (cat. 7619) were
obtained from the NIH AIDS Research and Reference Reagent Program.
Peptide pools were prepared so that each peptide was equally
represented. One pool was made for HIV-tat (peptide 1–23), SIV-tat
(peptide 1–30) and SIV-nef (peptide 1–64) peptides and three
peptide pools (gagA: peptide 1–33; gagB: peptide 34–89; gagC:
peptide 90–125) were made to encompass the entire gag region of
SIV. Similarly four (envA: peptide 1–60; envB; peptide 61–124; envC:
peptide 125–168; envD: peptide 169–211) and three (envA: peptide
1–60; envB; peptide 61–124; envC: peptide 125–218) peptide pools
were prepared to encompass the entire env region of SHIV162P3 and
SIV-env regions, respectively. For all positive control wells PMA
(50 ng/ml) and Ionomycin (1 μg/ml) were used. Negative controls
had no antigen/mitogen stimulation. Pooled peptides were added to
cells at a ﬁnal concentration of 1 μg/ml for each individual peptide.
The numbers of spot forming cells were counted using the KS
Elispot system (Zellnet Consulting Inc.). The mean number of spots
per duplicate or triplicate well was calculated and the results were
considered positive if the number of SFC for 2×105 cells was ≥10 per
well and greater than two-fold that of the negative control (medium
only) wells plus 2 standard deviations.
Virus neutralization assay
Neutralization of SHIV162P3 and primary SIVMAC251 was measured
as a function of reduction in luciferase reporter gene expression after a
single round of infection in TZM-bl cells as described (Monteﬁori,
2004). TZM-bl cells were obtained from the NIH AIDS Research and
Reference Reagent Program. Brieﬂy, 200 TCID50 of virus was incubated
with serial three-fold dilutions of serum in triplicate in a total volume
of 150 μl for 1 h at 37 °C in 96-well ﬂat-bottom cell culture plates
(Costar). Freshly trypsinized cells (10,000 cells in 100 μl of growth
medium containing 75 μg/ml DEAE dextran) were added to each well.
Positive and negative controls were kept with this assay. After
incubation, 100 μl of cells was transferred to 96-well black solid
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substrate solution as described by the supplier (Promega). Neutraliza-
tion titers were deﬁned as the serum dilution at which relative
luminescence units (RLU) were reduced 50% compared to virus
control wells after subtraction of background RLUs. Assay stocks of
primary SIVMAC251 and SHIV162P3 were prepared in human PBMC.
Neutralizing antibodies against TCLA SIVMAC251 were assessed in
CEMx174 cells as described previously (Monteﬁori et al., 1996). Brieﬂy
50 μl of cell-free virus (5000 TCID50) was added to multiple dilutions
of test serum in 100 μl of growth medium in triplicate wells of 96-well
microtiter plates and incubated for 1 h at 37 °C. Cells (7.5×104) in
100 μl of growth medium were added and incubated until extensive
syncytium formation and nearly complete cell-killing were evident
microscopically in virus control wells. Cell densities were reduced and
medium replaced after 3 days incubation in cases where it took longer
than 3 days to reach the assay end-point. Viable cells were stained
with Finter's neutral red in poly-L-lysine coated plates. Per-
cent protection from virus-induced cell-killing was determined by
calculating the difference in absorption (A540) between test wells
(cells+serum sample+virus) and virus control wells (cells+virus),
dividing this result by the difference in absorption between cell
control wells (cells only) and virus control wells and multiplying by
100. Nab titers are expressed as the reciprocal of the serum dilution
required to protect 50% of cells from virus-induced killing. This cut-off
corresponds to an approximate 90% reduction in p24 antigen
synthesis. An assay stock of TCLA-SIVMAC251 was prepared in H9 cells.
Statistical analysis
Graphical presentation and statistical analysis of the results were
performed by one-way analysis of variance or the Student t test using
the GraphPad Prism 4.0 (GraphPad Software Inc., San Diego, CA).
Plasma VLs comparison between immunized and control challenged
macaque was determined by nonparametric Mann–Whitney t test.
Correlation between plasma VL and antigen speciﬁc cytokine res-
ponses was determined using Spearman rank correlation test using
Prism software. For all statistical analysis, results were considered
signiﬁcant if pb0.05.
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